Stock DNA
Pharmaceuticals & Biotechnology
DKK 537 Million ()
NA (Loss Making)
NA
0.00%
-0.94
-246.71%
15.25
Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Jun 2025)
Net Profit:
-18 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
187.16%
0%
187.16%
6 Months
163.54%
0%
163.54%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Bioporto A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.39%
EBIT Growth (5y)
-9.78%
EBIT to Interest (avg)
-48.82
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.71
Sales to Capital Employed (avg)
0.36
Tax Ratio
8.84%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.72
EV to EBIT
-5.56
EV to EBITDA
-5.72
EV to Capital Employed
40.04
EV to Sales
14.27
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-720.02%
ROE (Latest)
-147.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
10.60
9.20
15.22%
Operating Profit (PBDIT) excl Other Income
-17.70
-17.30
-2.31%
Interest
1.50
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-18.10
-15.80
-14.56%
Operating Profit Margin (Excl OI)
-1,729.40%
-1,942.70%
21.33%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 15.22% vs 19.48% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -14.56% vs 19.39% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
36.20
31.00
16.77%
Operating Profit (PBDIT) excl Other Income
-73.10
-57.50
-27.13%
Interest
0.80
0.60
33.33%
Exceptional Items
0.00
-1.00
100.00%
Consolidate Net Profit
-68.20
-56.30
-21.14%
Operating Profit Margin (Excl OI)
-2,081.80%
-1,943.40%
-13.84%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 16.77% vs 6.90% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -21.14% vs 25.82% in Dec 2023
About Bioporto A/S 
Bioporto A/S
Pharmaceuticals & Biotechnology
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Company Coordinates 
Company Details
Tuborg Havnevej 15, St. , HELLERUP None : 2900
Registrar Details






